Migration of Lipid Nanoparticles away from the Deltoid muscle and into Vital Organs was Planned According to BioNTech CEO Ugur Sahin
Submitted by Harold Saive
Contrary to the official narrative, in September of 2020. BioNTech CEO Ugur Sahin claimed:
“For the Covid-19 candidate vaccine we have chosen lipid nanoparticles that promote migration from the muscle cells into lymph nodes.”
The following CHD article addresses the migration of the lipid nanoparticles into the lymph nodes but also “circulated throughout the body and accumulated in large concentrations in organs and tissues, including the spleen, bone marrow, liver, adrenal glands and — in “quite high concentrations” — in the ovaries.”
_____________________
(CHD 6/17/2021) Inventor of mRNA Technology: Vaccine Causes Lipid Nanoparticles to Accumulate in ‘High Concentrations’ in Ovaries
On the “Dark Horse Podcast,” Dr. Robert Malone, creator of mRNA vaccine technology, said the COVID vaccine lipid nanoparticles — which tell the body to produce the spike protein — leave the injection site and accumulate in organs and tissues.
Prior to the Japanese study’s disclosure, the public was led to believe by regulators and vaccine developers that the spike protein produced by mRNA COVID vaccines stayed in the shoulder where it was injected and was not biologically active — even though regulators around the world had a copy of the study which showed otherwise.
https://
_____________________
Coronona Investigative Committee – Prof. Ulrike Kammerer (Whistleblower)
Links to articles and documents provided in video pinned comment
https://odysee.com/@Corona-
Highlights:
– (LIE #1) mRNA lipid nanoparticles not designed to stay in arms as claimed by propaganda. The lipid NP’s were always intended to deploy to lymph nodes.
– (LIE #2) Pfizer lied when they claimed vials should remain at -80 deg C. This lie was to expedite vaccine deployment. Currently there is no requirement for deep refrigeration of this product
– Listen for the comment about microscopy image chracterized as “Cells with arms that move”.
– Deliberate suppression of the immune system creates an auto-immune condition described as “VAIDS” “Vaccine Induced Auto-immune Deficiency)
German: (2 SEP 2020) Teil des Covid-19-Impfstoffes könnte aus Österreich kommen
English: (2 SEP 2020) Part of the Covid-19 vaccine could come from Austria
https://www.diepresse.com/
Quote German to English (Google)
Depending on how these lipid nanoparticles are constructed on the surface, they behave differently. BioNTech CEO Ugur Sahin: “For the Covid-19 candidate vaccine we have chosen lipid nanoparticles that promote migration from the muscle cells into lymph nodes. Dendritic (antigen-presenting; note) cells then present the resulting S-protein to the immune system. We have in According to the early data published so far, both a strong antibody reaction of the B cells and the formation of specific CD4-positive and CD8-positive T cells were observed.The CD4 cells promote a protective immune response, the CD8 cells remain in the blood for a long time inhibit the virus from multiplying in infected cells. “
______________________________
Google Translation – German-English
Teil des Covid-19-Impfstoffes könnte aus Österreich kommen
English: “Part of the Covid-19 vaccine could come from Austria”
https://www.diepresse.com/
The Lower Austrian biotech company Polymun is involved in the Pfizer and BioNTech corona vaccine project.
More than 170 biotech companies worldwide are competing for Covid-19 vaccines. Polymun from Klosterneuburg is involved in one of the projects that is currently the most advanced worldwide – by US pharmaceutical company Pfizer and German biotechnology company BioNTech. It produces important parts for the candidate vaccine doses for the clinical studies, including the phase III study that has already started. Pfizer boss Albert Bourla, BioNTech CEO Ugur Sahin and Polymun managing director Dietmar Katinger explained this in an interview with the APA.
“We are one of the world’s largest vaccine manufacturers and have been active in this field for decades. We have been working with BioNTech (Mainz; note) since 2018 on an mRNA vaccine against influenza. When it became clear in February of this year that the If the newly identified SARS-CoV-2 virus strain could develop into what we now call the Covid-19 pandemic, we have also teamed up with BioNTech for a coronavirus vaccination and prioritized the project, “said Pfizer CEO Bourla on Tuesday as part of a short visit to the Lower Austrian biotech company Polymun, which emerged from the research of BOKU biotech pioneer Hermann Katinger and is now managed by his son, Dietmar Katinger.
The decision was made very quickly. Ugur Sahin, CEO of the German BioNTech, which pursues numerous development projects for drugs (e.g. oncologics) and for vaccines based on mRNA and other technologies: “The agreement with Pfizer on the Covid-19 project was concluded quickly and rather informally. We did Initially, 20 vaccine candidates were developed and tested to prevent infection with the virus. The preclinical tests were carried out on mice and rhesus monkeys. Our lead candidate BNT162b2 has been in clinical phase II / III (efficacy, safety on a large scale; note) since July. ”
These are virus genetic material fragments that are already suitable for the expression of SARS-CoV-2. “This mRNA leads to the production of the harmless, entire spike (S) protein of the coronavirus in human cells. These pieces of RNA are 3800 base pairs long and consist of around 1200 amino acids,” explained Sahin. In a phase I / II clinical study, two injections of the vaccine candidate with an interval of 21 days showed a stronger immune response than in people who “naturally” got and survived a SARS-CoV-2 infection. “We want to generate a stronger and longer-lasting protective immune response in the vaccinated.”
“Master the generation of liposomes”
In principle, there are several advantages to mRNA vaccines. “The vaccine is injected into a muscle. The body’s own cells then produce the virus S-protein themselves, against which the immune system generates a protective response. You do not need to produce antigens in cell cultures, etc., there can be no contamination,” he explained Expert who has been working with RNA technology since 1998 and worked at the University of Mainz before BioNTech was founded.
But for a vaccine, the mRNA has to be packaged in suitable transport vehicles. This is where Polymun comes in. “We have mastered the production of liposomes or lipid nanoparticles with GMP (pharmaceutical; note) quality. We can transfer production from the laboratory to larger quantities for industrial vaccine production,” said Dietmar Katinger.
Depending on how these lipid nanoparticles are constructed on the surface, they behave differently. Sahin: “For the Covid-19 candidate vaccine we have chosen lipid nanoparticles that promote migration from the muscle cells into lymph nodes. Dendritic (antigen-presenting; note) cells then present the resulting S-protein to the immune system. We have in According to the early data published so far, both a strong antibody reaction of the B cells and the formation of specific CD4-positive and CD8-positive T cells were observed.The CD4 cells promote a protective immune response, the CD8 cells remain in the blood for a long time inhibit the virus from multiplying in infected cells. ”
Development continues
In the case of the BioNTech candidate vaccine, Polymun expert Andreas Wagner constructed lipid nanoparticles with a size of 50 to one hundred nanometers (nanometers: billionths of a meter; note) that can only be made visible under an electron microscope. Katinger: “We produced the BioNTech vaccine candidates for the clinical trials.”
The development continues. The Polymun managing director: “We are working on producing one million cans per batch and are also making the technology available to others who will also start production for BioNTech / Pfizer.”
In the meantime, we are eagerly awaiting the results of the efficacy study with BNT162b2. Pfizer CEO Albert Bourla: “Our Phase III studies with BioNTech are currently running at 125 clinics in the USA, Brazil and Argentina. More than 20,000 of the planned 30,000 test subjects have already been enrolled. 15,000 will receive the candidate vaccines, 15,000 a placebo. If we have enough ‘events’ (infections with SARS-CoV-2; note), the study will be ‘unblinded’. So far, nobody knows who is receiving what. Then we will know more about the vaccine candidate and its properties. ”
Results expected in October
For the vaccinations – two injections 21 days apart – a dose of 30 micrograms is used. According to the results from the initial investigations (phase I / II), this also leads to a good immune response in older people. The candidate vaccine has been well tolerated so far. Mild feverish reactions in about 20 percent of the subjects were observed. That is in line with expectations.
The results of the crucial phase III study, the results of which will be included in the approval of the vaccine, should possibly be available in October. Bourla: “The approval authority will receive the data as soon as it is available. Approval will probably go very quickly if the results of the efficacy test are positive. We hope to be able to produce up to a hundred million doses of the vaccine this year, around year 1 next. 3 billion. Pfizer has three manufacturing facilities in the US and one in Europe, plus two BioNTech manufacturing facilities in Germany.
Another production site will be Polymun in Klosterneuburg. Despite all efforts worldwide, the Pfizer CEO is cautious: “The need for Covid-19 vaccines will initially be greater than production.”